The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The use of AI for analyzing genetic and molecular data in CLL
Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses the emergent use of artificial intelligence (AI) in chronic lymphocytic leukemia (CLL). Dr Agathangelidis explains how applying a different approach in analyzing molecular data could help generate novel findings in CLL. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
